MTOR and cancer: PI3K/mTOR signalling pathway activation has been correlated with poor prognosis and resistance to chemotherapy.3 Thus, this pathway remains an investigational target for cancer therapeutics, including rapalogs or TOR-KIs such as MLN0128/TAK-228.11 However, rapalogs have limited anticancer activity and the therapeutic window for TOR-KIs remains to be established.